Lukas Kessler1,2, Justin Ferdinandus3,2, Nader Hirmas3,2, Fadi Zarrad3,2, Michael Nader3,2, David Kersting3,2, Manuel Weber3,2, Sandra Kazek3,2, Miriam Sraieb3,2, Rainer Hamacher2,4, Katharina Lueckerath3,2, Lale Umutlu2,5, Wolfgang P Fendler3,2, Christoph Rischpler3,2. 1. Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; lukas.kessler@uk-essen.de. 2. German Cancer Consortium, University Hospital Essen, University of Duisburg-Essen, Essen, Germany. 3. Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany. 4. Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; and. 5. Institute of Diagnostic and Interventional Radiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Abstract
Fibroblast activation protein inhibitor (FAPI) PET/CT is a new tool in the diagnostic workup of cancer. With a growing volume of applications, pitfalls and common findings need to be considered for 68Ga-FAPI PET/CT image interpretation. The aim of this study was to summarize common findings and report pitfalls in 68Ga-FAPI PET/CT. Methods: Ninety-one patients underwent whole-body PET/CT with either FAPI-04 (n = 25) or FAPI-46 (n = 66). Findings were rated in a consensus session of 2 experienced readers. Pitfalls and common findings were defined as focal or localized uptake above the background level and categorized as unspecific or nonmalignant and grouped into degenerative, muscular, scarring/wound-healing, uterine, mammary gland, and head-and-neck findings. The frequency of findings was reported on a per-patient and per-group basis, and SUVmax, SUVmean, and SUVpeak were measured. Results: Non-tumor-specific uptake was found in 81.3% of patients. The most frequent finding was uptake in degenerative lesions (51.6%), with a mean SUVmax of 7.7 ± 2.9, and head-and-neck findings (45.1%). Except for the salivary glands, the uptake values did not differ between 10 and 60 min after injection in most findings. Uterine uptake was found in most women (66.7%), with a mean SUVmax of 12.2 ± 7.3, and uptake correlated negatively with age (SUVmax, r = -0.6, P < 0.01; SUVpeak, r = -0.57, P < 0.01; SUVmean, r = -0.58, P < 0.01). Conclusion: Pitfalls include non-tumor-specific 68Ga-FAPI uptake in degenerative lesions, muscle, the head and neck, scarring, the mammary glands, or the uterus. Here, we summarize the findings to help readers avoid common mistakes at centers introducing 68Ga-FAPI PET/CT.
Fibroblast activation protein inhibitor (FAPI) PET/CT is a new tool in the diagnostic workup of cancer. With a growing volume of applications, pitfalls and common findings need to be considered for 68Ga-FAPI PET/CT image interpretation. The aim of this study was to summarize common findings and report pitfalls in 68Ga-FAPI PET/CT. Methods: Ninety-one patients underwent whole-body PET/CT with either FAPI-04 (n = 25) or FAPI-46 (n = 66). Findings were rated in a consensus session of 2 experienced readers. Pitfalls and common findings were defined as focal or localized uptake above the background level and categorized as unspecific or nonmalignant and grouped into degenerative, muscular, scarring/wound-healing, uterine, mammary gland, and head-and-neck findings. The frequency of findings was reported on a per-patient and per-group basis, and SUVmax, SUVmean, and SUVpeak were measured. Results: Non-tumor-specific uptake was found in 81.3% of patients. The most frequent finding was uptake in degenerative lesions (51.6%), with a mean SUVmax of 7.7 ± 2.9, and head-and-neck findings (45.1%). Except for the salivary glands, the uptake values did not differ between 10 and 60 min after injection in most findings. Uterine uptake was found in most women (66.7%), with a mean SUVmax of 12.2 ± 7.3, and uptake correlated negatively with age (SUVmax, r = -0.6, P < 0.01; SUVpeak, r = -0.57, P < 0.01; SUVmean, r = -0.58, P < 0.01). Conclusion: Pitfalls include non-tumor-specific 68Ga-FAPI uptake in degenerative lesions, muscle, the head and neck, scarring, the mammary glands, or the uterus. Here, we summarize the findings to help readers avoid common mistakes at centers introducing 68Ga-FAPI PET/CT.
Authors: Jochen Tillmanns; Daniel Hoffmann; Yasmin Habbaba; Jan D Schmitto; Daniel Sedding; Daniela Fraccarollo; Paolo Galuppo; Johann Bauersachs Journal: J Mol Cell Cardiol Date: 2015-08-28 Impact factor: 5.000
Authors: W J Rettig; P Garin-Chesa; H R Beresford; H F Oettgen; M R Melamed; L J Old Journal: Proc Natl Acad Sci U S A Date: 1988-05 Impact factor: 11.205
Authors: Sara Sheikhbahaei; Ali Afshar-Oromieh; Matthias Eiber; Lilja B Solnes; Mehrbod S Javadi; Ashley E Ross; Kenneth J Pienta; Mohamad E Allaf; Uwe Haberkorn; Martin G Pomper; Michael A Gorin; Steven P Rowe Journal: Eur J Nucl Med Mol Imaging Date: 2017-08-01 Impact factor: 9.236
Authors: Jennifer M Milner; Lara Kevorkian; David A Young; Debra Jones; Robin Wait; Simon T Donell; Emma Barksby; Angela M Patterson; Jim Middleton; Benjamin F Cravatt; Ian M Clark; Andrew D Rowan; Timothy E Cawston Journal: Arthritis Res Ther Date: 2006-01-03 Impact factor: 5.156
Authors: Anastasia Loktev; Thomas Lindner; Eva-Maria Burger; Annette Altmann; Frederik Giesel; Clemens Kratochwil; Jürgen Debus; Frederik Marmé; Dirk Jäger; Walter Mier; Uwe Haberkorn Journal: J Nucl Med Date: 2019-03-08 Impact factor: 10.057
Authors: Katharina Dendl; Stefan A Koerber; Sebastian Adeberg; Manuel Röhrich; Clemens Kratochwil; Uwe Haberkorn; Frederik L Giesel Journal: Eur J Nucl Med Mol Imaging Date: 2021-02-04 Impact factor: 9.236
Authors: Aleksander Kosmala; Sebastian E Serfling; Niklas Dreher; Thomas Lindner; Andreas Schirbel; Constantin Lapa; Takahiro Higuchi; Andreas K Buck; Alexander Weich; Rudolf A Werner Journal: Cancers (Basel) Date: 2022-05-25 Impact factor: 6.575
Authors: Sebastian E Serfling; Philipp E Hartrampf; Yingjun Zhi; Takahiro Higuchi; Steven P Rowe; Lena Bundschuh; Markus Essler; Andreas K Buck; Ralph Alexander Bundschuh; Rudolf A Werner Journal: Clin Nucl Med Date: 2022-04-19 Impact factor: 10.782
Authors: Nika Guberina; Lukas Kessler; Christoph Pöttgen; Maja Guberina; Martin Metzenmacher; Ken Herrmann; Maja Mucha; Christoph Rischpler; Frank Indenkämpen; Jens T Siveke; Jürgen Treckmann; Lale Umutlu; Stefan Kasper; Wolfgang P Fendler; Martin Stuschke Journal: Sci Rep Date: 2022-09-28 Impact factor: 4.996
Authors: Vera Wenter; Alexander Kretschmer; Lena M Unterrainer; Simon Lindner; Lennert Eismann; Jozefina Casuscelli; Franz-Josef Gildehaus; Vinh Ngoc Bui; Nathalie L Albert; Adrien Holzgreve; Leonie Beyer; Andrei Todica; Matthias Brendel; Clemens C Cyran; Alexander Karl; Christian G Stief; Stephan T Ledderose; Marcus Unterrainer; Peter Bartenstein Journal: Eur J Nucl Med Mol Imaging Date: 2022-03-24 Impact factor: 10.057